Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

A research team from the University of Central Florida's College of Medicine conducted a study of patient perceptions of ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a biomarker, one researcher said.

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

Rheumatoid arthritis (RA ... for a medication adjustment or other change in treatment. Research has also found that RA flares may contribute substantially to worsening cardiovascular comorbidity, ...

US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...

The worsening skin symptoms typically occurred 10 days after vaccination ... Chronic heart disease Chronic lung disease Chronic kidney disease Diabetes Obesity Experts are currently unsure if ...